[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Icahn School of Medicine at Mount Sinai\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":564},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,168,0,25,[9,47,75,102,128,148,167,187,208,233,251,277,303,321,345,364,390,409,435,454,476,493,509,528,540],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053867",false,"NCT07638384","Evaluation of Muscle Oxygen With MRI","Effect of External Pressure and Muscle Contraction on Soft Tissue Oxygenation Measured With Functional MRI","Inclusion Criteria:\n\n* Alert and oriented.\n* Able to lift 10lbs. and hold for 30 seconds\n* Not claustrophobic.\n* Intact sensation in right upper extremity.\n\nExclusion Criteria:\n\n* Latex allergy or allergy to isopropyl alcohol.\n* Skin injury or decreased sensation on right upper extremity.",true,"ALL","20 Years","64 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"NA","Demonstration of soft tissue hypoxia on MRI using external compression and muscle contraction.",[28],"Muscle Oxygenation",[30,31,32,33],"muscle","magnetic resonance imaging","external pressure","muscle contraction","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":22},"2026-08",{"date":42,"type":22},"2029-05-07",{"name":44,"class":45},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":48,"slug":4,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100613002","NCT07260916","Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation","Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation (MINUTE) Trial","MINUTE","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 80 years\n* Non-traumatic, spontaneous, supratentorial, non-thalamic, BGH of volume ≥ 20 mL, as determined by the treating physician using ABC\u002F2 method\n* NIHSS ≥ 6 at presentation\n* Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA) is performed and does not show an underlying vascular lesion\n* Pre-ICH mRS 0-2 Informed consent from patient or legally authorized representative (LAR) to participate in the trial, wherein patient\u002FLAR's stated wishes are to pursue lifesaving therapies as opposed to early withdrawal of care (explicitly explained as \\\u003C7 days following ictus)\n* The treating physician anticipates that surgery can be initiated \\\u003C120 min from randomization\n* Randomization can occur ≤16 hours from LKW\n\nExclusion Criteria:\n\n* Suspected secondary cause for the ICH, such as an underlying vascular malformation (cavernous malformation, arteriovenous malformation, etc.), aneurysm, neoplasm, hemorrhagic transformation of an underlying ischemic infarct; or venous infarct Infratentorial or thalamic hemorrhage\n* Midbrain extension\u002Finvolvement\n* Coagulopathy defined as international normalized ratio (INR) \\> 1.4\n* Elevated activated Partial Thromboplastin Time (aPTT) \\> 40 s\n* Concurrent use of direct oral anticoagulants or low molecular weight heparin at ICH onset\n* Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency\n* Platelet count \\\u003C100 x 103 cells\u002Fmm3, or known platelet dysfunction (reversal of coagulopathy is not allowed) GCS score \\\u003C7 at presentation\n* Evidence of active infection indicated by fever ≥100.7 °F and\u002For open draining wound at the time of enrollment\n* Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 365 days\n* Intraventricular extension of the hemorrhage is visually estimated to involve \\> 50% of either of the lateral ventricles\n* Pregnancy (women of childbearing potential must have a negative pregnancy test to participate)\n* Based on investigator's judgment, the patient does not have the necessary mental capacity to participate or is unwilling to comply with the protocol follow-up schedule\n* Current participation in another interventional (drug or device) trial\n* Pre-existing Do Not Resuscitate (DNR)\u002FDo Not Intubate (DNI) status\n* History of severe dementia","18 Years","80 Years",{"count":57,"type":22},300,[25],"MINUTE is a prospective, multi-center, randomized, controlled, blinded assessor, adaptive enrichment design, clinical trial. Eligible patients with spontaneous BGH ≥20 mL will be randomized 1:1 to either minimally invasive endoscopic SCUBA evacuation plus standard medical management or standard medical management alone; the time of randomization will be used to classify participants in one of two cohorts: 1) those randomized \\\u003C8 hours from onset, and 2) those randomized 8-16 hours from onset. Randomization is targeted to occur within 120 min of arrival to the randomizing center's Emergency Department (ED), and initiation of surgery is targeted to occur within 120 min of randomization. Participants will be followed at 30, 90, 180, and 365 days to assess for adverse events (AEs) and utility-weighted modified Rankin Scale (UW-mRS).",[61],"Basal Ganglia Intracerebral Hemorrhage",[63,64,65],"Basal Ganglia","SCUBA","Intracerebral Hemorrhage","2026-06-25",{"date":68,"type":38},"2026-06-29",{"date":70,"type":22},"2026-07-15",{"date":72,"type":22},"2030-06-30",{"name":44,"class":45},2,{"id":76,"slug":4,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100366007","NCT04045665","Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","PACES","Inclusion Criteria:\n\n* Patients of age ≥18 years who undergo isolated CABG for coronary artery disease\n* POAF that persists for \\>60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery\n\nExclusion Criteria:\n\n* Clinical history of either permanent, persistent or paroxysmal atrial fibrillation\n* Any pre-existing clinical indication for long-term OAC\n* Any absolute contraindication to OAC\n* Planned use of post-operative dual antiplatelet therapy (DAPT)\n\n  a. This includes, but is not limited to, patients with recent PCI with drug-eluting or bare-metal stent.\n* Cardiogenic shock\n* Major perioperative complication\\* occurring between CABG and randomization\n\n  a. including, but not limited to, stroke, TIA, MI, major bleeding (BARC type 4 bleeding), severe sepsis, renal failure requiring dialysis, or need for reoperation due to bleeding (e.g. pericardial tamponade).\n* Concomitant left atrial appendage closure during CABG\n* Concomitant valve surgery during CABG or prior valve surgery (including aortic, mitral, tricuspid or pulmonary)\n* Concomitant mitral valve annuloplasty during CABG\n* Concomitant carotid artery endarterectomy during CABG\n* Concomitant aortic root replacement during CABG\n* Concomitant surgery for AF during CABG\n* Liver cirrhosis or Child-Pugh Class C chronic liver disease\n* Pharmacologic therapy with an investigational drug or device within 30-days prior to randomization or plan to enroll patient in an investigational drug or device trial during participation in this trial\n* Pregnancy at the time of randomization\n* Unable or unwilling to provide inform consent\n* Unable or unwilling to comply with the study treatment and follow-up\n* Existence of underlying disease that limits life expectancy to less than one year",{"count":82,"type":22},3200,[84],"PHASE3","The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.\n\nAll patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.",[87,88,89],"Atrial Fibrillation","Stroke","Bleeding",[91,92,93],"Anticoagulation","Antiplatelet Therapy","Post Operative Atrial Fibrillation",{"date":95,"type":38},"2026-06-26",{"date":97,"type":38},"2019-12-13",{"date":99,"type":22},"2026-08-31",{"name":44,"class":45},106,{"id":103,"slug":4,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":46},"100644848","NCT07675044","Quantifying the Burden of Type 2 (T2) Inflammation in Asthma","QUANTAS-PC: Quantifying the Burden of Type 2 (T2) Inflammation in Asthma in Primary Care and Community Specialty Practices","QUANTAS","Participant Inclusion Criteria\n\n* Age 18 years and older\n* Ability to consent and comply with protocol assessments\n* Pre-existing diagnosis of asthma and has started treatment\n\nParticipant Exclusion Criteria\n\n* Participant deemed medically ineligible per the opinion of the investigator\n* History of respiratory\u002Flung disease other than asthma (e.g., COPD, emphysema, chronic bronchitis, tuberculosis, cystic fibrosis, lung cancer, recurrent pneumonia or other chronic lung disease)\n* Participants who meet criteria for GINA 5, severe asthma (ICS + additional controllers)\n* Current Enrollment in an asthma intervention trial that could affect asthma outcomes clinically and T2 biomarkers\n* Visit with a specialist (i.e. Pulmonologist or Allergist) in the past year who is measuring FeNO levels",{"count":110,"type":22},200,"OBSERVATIONAL","This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.",[114,115],"Asthma","Type 2 Asthma",[114,117,118],"Eosinophils","Exhaled Nitric Oxide","NOT_YET_RECRUITING","2026-06-23",{"date":122,"type":38},"2026-06-30",{"date":124,"type":22},"2026-07",{"date":126,"type":22},"2027-05",{"name":44,"class":45},{"id":129,"slug":4,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":74},"100595943","NCT07039019","Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis","Pilot, RandOmized Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis","PROSPECT","Inclusion Criteria:\n\n* All adult patients with diagnosis of non-specific pleuritis as determined by pleural biopsy with a negative serologic autoimmune profile (ANA, ANCA, anti-DS DNA, anti-SS A\u002FB, anti-centromere, RF, anti-CCP) are eligible\n\nExclusion Criteria:\n\n* Chronic\u002Ffibrinous pleuritis\n* Positive autoimmune serologic workup\n* A contraindication to corticosteroids\n* Empyema\n* Patients already receiving corticosteroids or other immunosuppressive medications for any other indication\n* Inability to obtain informed consent due to cognitive, neurologic or psychiatric impairment",{"count":136,"type":22},40,[138],"EARLY_PHASE1","This research study aims to evaluate whether corticosteroids help prevent the recurrence of pleural effusions in patients with non-specific pleuritis diagnosed through pleural biopsy. It can lead to recurrent fluid buildup in the lungs, causing discomfort and requiring additional medical interventions. There is no established treatment to prevent recurrence, and this study seeks to determine whether steroids reduce fluid buildup or cause complications.\n\nThere will be two groups: one receiving corticosteroids (standard of care in the institution) and one not receiving corticosteroids (intervention group). The participation will last approximately 6 months, with in-person visits every 2 weeks for the first month, then monthly, along with possible telephone follow-ups. The study will monitor for pleural effusion recurrence, need for additional procedures, and potential side effects of corticosteroids.\n\nThis is a pilot study. Although there are forty people expected to take part in this research study based on institutional data, the number of patients included in the study will be determined by the number of patients with non-specific pleuritis diagnosed during the study period.",[141],"Pleuritis, Non-specific",{"date":66,"type":38},{"date":144,"type":38},"2025-05-29",{"date":146,"type":22},"2027-06-30",{"name":44,"class":45},{"id":149,"slug":4,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":16,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":46},"100491146","NCT05675332","Effects of Stereotype Threat on Impulsivity and Its Relation to Alcohol Use in African Americans: An fMRI Study","Inclusion Criteria:\n\n* Between 21 and 35 years of age (inclusive);\n* Fluent in English;\n* Right-handed\n\nExclusion Criteria:\n\n* Younger than 21 years of age;\n* Left-handed","21 Years","35 Years",{"count":156,"type":22},280,[25],"The purpose of this study is to investigate the behavioral and neural correlates of stress exposure. Results from this study will enrich the understanding of how sociocultural, behavioral, and neural factors combine to influence alcohol use.",[160],"Alcohol Drinking",{"date":66,"type":38},{"date":163,"type":38},"2022-12-09",{"date":165,"type":22},"2027-01-31",{"name":44,"class":45},{"id":168,"slug":4,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":46},"100644539","NCT07671599","Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE)","Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE): A Pilot Study","PERUSE","Inclusion Criteria:\n\n* singleton pregnancy\n* no prior diagnosis of diabetes (gestational included)\n* scheduled term cesarean delivery in Mount Sinai Health System\n* aged 18-50 years\n\nExclusion Criteria:\n\n* preexisting diabetes mellitus\n* diagnosis of gestational diabetes mellitus (GDM) in the current pregnancy, based on standard prenatal screening\n* known endocrine disorder affecting glucose metabolism (such as Cushing syndrome, poorly controlled thyroid disorder, etc.)\n* use of antenatal steroids within the two weeks prior to delivery","50 Years",{"count":176,"type":22},150,"This prospective pilot study is exploratory in nature and is designed to evaluate the validity of continuous glucose monitor (CGM) use for perioperative glucose surveillance during scheduled Cesarean delivery for nondiabetic patients. Primary objective is characterization of perioperative glucose trends during elective Cesarean delivery in patients without diabetes and exploratory analyses will describe perioperative glucose patterns captured by CGM. Secondary objective is to examine rates of and associations with post-operative complications, including surgical site infections.",[179],"Dysglycemia","2026-06-22",{"date":95,"type":38},{"date":183,"type":22},"2026-09",{"date":185,"type":22},"2028-05",{"name":44,"class":45},{"id":188,"slug":4,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":46},"100451563","NCT05160129","Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder","All participants will receive ALIC DBS for OCD. DBS received a Humanitarian Device Exemption (HDE) in 2009 with an indication for bilateral stimulation of the ALIC as an adjunctive treatment to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-refractory OCD in adult patients who have failed at least three SSRIs. Additionally, more stringent criteria have been selected for defining treatment-resistance in this protocol, as indicated below.\n\nINCLUSION CRITERIA:\n\n* 18 years of age or older\n* Primary psychiatric diagnosis of Obsessive-Compulsive Disorder (OCD, per DSM-5 criteria)\n* Meets FDA Humanitarian Device Exemption (HDE) criteria for indication\n* Has elected to receive clinically indicated DBS for OCD with a directional system outside of this research study, as determined by treating clinician(s) and per current clinical practice\n* Minimum of a five-year history of treatment-refractory OCD with substantial functional impairment\n* Failure of an adequate trial of at least three of the following SSRIs: Fluoxetine, Fluvoxamine, Citalopram, Escitalopram, Sertraline, Paroxetine\n* Failure of an adequate trial of clomipramine\n* Failure of an adequate trial of one or more of the aforementioned antidepressants in combination with at least one of the following augmentation agents: Haloperidol, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole\n* Failure of an adequate trial of Cognitive Behavioral Therapy (CBT), defined as 25 hours of documented exposure and response prevention (ERP) by an expert therapist\n* Minimum score of 25 on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) at preoperative baseline\n* Ability to undergo preoperative MRI\n* English proficiency\n* Capacity to provide written informed consent\n* Willing and able to comply with all device operation and study-related procedures\n\nEXCLUSION CRITERIA:\n\n* Ineligible or unwilling to receive ALIC DBS for OCD\n* Contraindications for general anesthesia, neurosurgery, or an MRI scan\n* Neurological disorder or other significant brain pathology, such as moderate \u002F marked cerebral atrophy, stroke, tumor, epilepsy, or previous neurosurgical procedures (excluding cingulotomy, which may be permitted if not contraindicated in the opinion of implanting neurosurgeon)\n* Unstable medical illness, chronic immunosuppression, and\u002For considerably reduced life-expectancy\n* Conditions requiring anticoagulant therapy which cannot be discontinued for the perioperative period, as required\n* Conditions requiring certain regular MRI scans or diathermy\n* Currently implanted with a cardiac pacemaker \u002F defibrillator or other implanted electrical device which may interfere with DBS stimulator or the function of which may be impacted by its implantation, in the opinion of evaluating neurosurgeon\n* Other primary Axis I disorder or history of psychosis, such as schizophrenia, psychosis in the context of depressive or manic episode.\n* Current or past history within the 6 months prior to DBS implantation of substance abuse or dependence (excluding nicotine and caffeine)\n* Active suicidal ideation with intent, suicide attempt within the last six months, more than three suicide attempts within the last two years, or serious suicide risk as determined by the study psychiatrists\n* Axis II disorders which, in the opinion of the study psychiatrist, may increases the risk of DBS to participants or cause study non-compliance\n* Patients who lack the capacity to for proper device usage and maintenance, in the opinion of the research team\n* Women who are pregnant",{"count":193,"type":22},22,[25],"Deep brain stimulation (DBS) is an effective treatment for people suffering from severe obsessive-compulsive disorder (OCD) whose symptoms have failed to improve after years and multiple methods of intervention. An effective DBS target for OCD is the anterior limb of the internal capsule (ALIC) brain region. On average 60% of all OCD patients have a clinically significant response to ALIC DBS. However, ALIC DBS may become even more effective with the ability to predict which specific ALIC connections in the brain need to be stimulated for each individual OCD patient. This study therefore investigates personalized stimulation to the ALIC that allows for precise modulation of brain circuits associated with individual OCD symptoms. The study aims to specify the ideal anatomical target for ALIC DBS for maximum therapeutic benefit in each patient.",[197],"Obsessive Compulsive Disorder (OCD)",[199,197,200,201],"Deep Brain Stimulation (DBS)","Anterior Limb of Internal Capsule (ALIC)","Circuit Modulation",{"date":66,"type":38},{"date":204,"type":38},"2021-08-13",{"date":206,"type":22},"2027-02-28",{"name":44,"class":45},{"id":209,"slug":4,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":217,"conditions":218,"keywords":222,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":46},"100206702","NCT01967511","Defining the Basis of Fibromuscular Dysplasia (FMD)","Defining the Basis of Fibromuscular Dysplasia: The Define-FMD Study","DEFINE","Inclusion Criteria:\n\n* Patients of any age and freely willing to participate. For patients \\\u003C 18 years of age consent will be via parents.\n* Fluency in either English or Spanish.\n* Signed, informed consent\n* For FMD, SCAD or CvAD subjects - a clinical diagnosis of FMD, SCAD or CvAD with fulfillment of standard diagnostic criteria.\n* For healthy controls - no clinical features of FMD, SCAD or CvAD and absence of any major ongoing systemic disease including any condition requiring hospitalization, immune suppression, intravenous or injected medications or that result in functional impairment in the performance of activities of daily living. Healthy controls will be matched to enrolled FMD patients on the basis of gender and approximate age (within a 5 year window of another FMD subject).\n\nExclusion Criteria:\n\n* Patients who have co-morbidities which reduces life expectancy to one year.\n* Patients with any solid organ or hematological transplantation, or those in whom transplantation is considered.\n* Active autoimmune disease.\n* Illicit drug use.\n* HIV positive.\n* Prior malignancy.\n* Any other form of vascular disease, including other arteriopathy coronary artery disease or peripheral vascular disease\n* Family history of arteriopathy other than FMD, SCAD or CvAD (e.g. Ehlers-Danlos syndrome)",{"count":216,"type":22},600,"The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.",[219,220,221],"Fibromuscular Dysplasia","Spontaneous Coronary Artery Dissection","Cervical Artery Dissection",[223,224,225,220,221],"Cross-sectional study","Fibromuscular dysplasia","Fibroblast",{"date":227,"type":38},"2026-06-24",{"date":229,"type":38},"2013-10-01",{"date":231,"type":22},"2030-12",{"name":44,"class":45},{"id":234,"slug":4,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":248,"leadSponsor":250,"locationsCount":46},"100644022","NCT07668817","Tract Closure in PCNL","Defining the Role of Hemostatic Agents in Percutaneous Nephrolithotomy: A Randomized Controlled Trial of Tract Closure Techniques","Inclusion criteria:\n\n* At least one stone ≥ 1.2cm\n* Scheduled to undergo planned PCNL\n* Age ≥ 18 years\n\nExclusion criteria:\n\n* Unable to provide informed consent\n* Pre-existing nephrostomy tube\n* Multi access cases\n* Stone in calyceal diverticulum\u002Fhydrocalyx\n* Preoperatively planned overnight admission for any reason\n* Infundibular stenosis\n* Coagulation disorders\n* Other significant anatomic abnormalities",{"count":240,"type":22},92,[25],"This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract closure, following uniform balloon occlusion, complete aspiration, and irrigation-free endoscopic assessment. The researchers hypothesize that adjunctive hemostatic agent use reduces perioperative hemoglobin decline compared with balloon tamponade alone and improves tract-related hemostasis outcomes.",[244],"Nephrolithiasis","2026-06-21",{"date":66,"type":38},{"date":124,"type":22},{"date":249,"type":22},"2028-06",{"name":44,"class":45},{"id":252,"slug":4,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":276},"100644138","NCT07665307","Delayed Toxicities Post-CAR-T","An Umbrella Observational Study to Determine Novel Actionable Biomarkers, Mechanisms, and Mitigation of Rare Chimeric Antigen Receptor T Cell (CAR-T) Toxicities in Relapsed\u002FRefractory Multiple Myeloma (RRMM)","Inclusion Criteria:\n\n* Subject is ≥18 years of age at the time of signing the informed consent form (ICF).\n* Subject must understand and voluntarily sign an ICF prior to any study-related assessments\u002Fprocedures being conducted.\n* Subject is willing and able to adhere to the study visit schedule and other protocol requirements.\n* All subjects must have documented diagnosis of MM and be eligible for commercial CAR-T therapy with cilta-cel. Patients planned for standard of care cilta-cel whose cell product is considered out of specification after manufacture will still be eligible to proceed with the current study protocol if proceeding with cilta-cel infusion\n* All patients must have ECOG Performance Status ≤ 2.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Subjects with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), primary amyloidosis (no active multiple myeloma), Waldenström's macroglobulinemia, or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)\n* Subjects with active plasma cell leukemia (defined as either 5% of peripheral blood white blood cell count comprised of plasma\u002FCD138+ cells or an absolute plasma cell count of 2 x 109\u002FL)\n* Subjects with active Central Nervous System (CNS) involvement with multiple myeloma\n* Cardiac conditions including:\n\n  * New York Heart Associated class 3 or 4 congestive heart failure\n  * Myocardial infarction or coronary artery bypass graft (CABG) ≤6 months prior to enrollment\n  * History of clinically significant ventricular arrhythmia\n  * History of severe non-ischemic cardiomyopathy\n* Stroke or seizure within 6 months of enrollment\n* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form\n* Any serious concurrent medical conditions that may make the patient non-evaluable or put the patient's safety at risk, per the discretion of the treating physician or PI\n* Patients with a positive PCR test for hepatitis B virus or hepatitis C virus indicating active infection. Patients with positive serologic testing indicating exposure will need confirmatory testing by PCR.\n* Patients who are seropositive for HIV\n* Prior or concurrent malignancy, except for the following:\n\n  * Adequately treated basal cell or squamous cell skin cancer or in-situ carcinoma.\n  * Non-muscle invasive bladder cancer treated within the last 24 months that is considered completely cured.\n  * Localized prostate cancer (N0M0):\n\n    * with a Gleason score of ≤6, treated within the last 24 months or untreated and under surveillance,\n    * with a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence; or\n    * any history of localized prostate cancer and receiving androgen deprivation therapy and considered to have a very low risk of recurrence per the discretion of the treating physician or PI\n  * Non-invasive cervical cancer treated within the last 24 months that is considered completely cured.\n  * Breast cancer: adequately treated lobular carcinoma in situ, or ductal carcinoma in situ, or history of localized breast cancer and receiving anti-hormonal agents and considered to have a very low risk of recurrence.\n  * Any other cancer from which the subject has been disease free for \\> 3 years prior to study entry, or considered cured with minimal risk of disease recurrence.\n* Prior treatment with CAR-T\n* Prior allogeneic stem cell transplant\n* Major cardiac surgery within 8 weeks prior to cilta-cel; all other major surgery within 4 weeks prior to cilta-cel.\n* Patients who are pregnant or breastfeeding\n* Subjects with following physical and laboratory test findings:\n\n  * Absolute neutrophil count \\\u003C 1 x 109\u002FL without growth factor support within 1 week, or absolute neutrophil count \\\u003C 0.5 x 109\u002FL for patients with documented Duffy-null blood typing\n  * Platelets \\\u003C 50 x 109\u002FL without transfusion support within 1 week\n  * Creatinine clearance \\\u003C 30 ml\u002Fmin according to the Cockroft-Gault formula:\n\n    * Female CrCl = \\[(140 - age in years) x weight in kg x 0.85\\] \u002F \\[72 x serum creatinine in mg\u002Fdl\\]\n    * Male CrCl = \\[(140 - age in years) x weight in kg x 1.00\\] \u002F \\[72 x serum creatinine in mg\u002Fdl\\]\n  * Total bilirubin ≥ 2 x ULN (≥ 3 x ULN if documented Gilbert's syndrome)\n  * AST or ALT ≥ 3x ULN\n  * Corrected serum calcium \\> 13.5 mg\u002FdL\n* Are also excluded:\n\n  * Prisoners or subjects who are involuntarily incarcerated\n  * Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness",{"count":258,"type":22},30,"This is an observational umbrella protocol evaluating toxicities after CAR-T therapy with ciltacabtagene autoleucel (cilta-cel) for RRMM, with a goal to identify key inflammatory features contributing to toxicities, define non-invasive biomarkers to guide clinical monitoring, and evaluate treatment strategies to reduce morbidity for patients. Toxicities of interest will include neurotoxicity, hematologic, and gastrointestinal events. Patients planned to receive cilta-cel as part of their standard of care multiple myeloma therapy will be enrolled. All patients will have baseline evaluation at the time of leukapheresis and cilta-cel infusion, as well as longitudinal blood, bone marrow, cerebrospinal fluid (CSF), and gastrointestinal (GI) samples collected for translational assessment. Patients who experience toxicities of interest as evaluated by their clinical team will undergo additional evaluation and sample collection, as guided by the involved organ system (e.g. CSF for neurologic toxicity, endoscopic evaluation with colonic biopsies for colitis), with monitoring for resolution of symptoms on therapy. Additional patients from Mount Sinai or other centers \\[University of California San Francisco (UCSF), Memorial Sloan Kettering Cancer Center (MSKCC)\\] who have previously been or will be treated with cilta-cel and are participating in institutional biobanks will similarly be included for ongoing sample collected per local protocols, and samples from patients experiencing toxicities of interest will be sent to Mount Sinai for analysis to supplement the prospective cohort.",[261],"Multiple Myeloma",[263,264,265,266,267,268],"multiple myeloma","myeloma","car-t toxicity","neurotoxicity","car-t","cilta-cel","2026-06-18",{"date":227,"type":38},{"date":272,"type":22},"2026-06",{"date":274,"type":22},"2029-06-18",{"name":44,"class":45},3,{"id":278,"slug":4,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":284,"minAge":54,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":287,"conditions":288,"keywords":291,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":46},"100519930","NCT06049953","Maternal And Infant Antipsychotic Study","Developmental Effects of Antenatal Exposure to Antipsychotics","MAIA","Inclusion Criteria:\n\n* Pregnant\n* Severe mental illness, including:\n\n  * Psychotic disorder (affective and nonaffective)\n  * Bipolar disorder\n  * History of psychiatric hospitalization, regardless of diagnosis\n* Able to complete study interviews and measures in English, Dutch, or Spanish\n\nExclusion Criteria:\n\n* Active substance use disorder in pregnancy\n* Insufficiently high-functioning to provide full informed consent and\u002For participate in study procedures","FEMALE",{"count":286,"type":22},74,"The goal of this observational study is to learn about maternal psychiatric course and infant development in pregnant individuals with severe mental illness, comparing those treated with antipsychotics to those treated with other medications or without medication. The main questions it aims to answer are:\n\n1. Is risk of psychiatric relapse different among individuals who take antipsychotic medication, other medication, or no medication?\n2. Are pregnancy and neonatal health outcomes different among individuals who take antipsychotic medication, other medication, or no medication?\n3. Do infant behavior and neurodevelopment differ among babies who were exposed to antipsychotic medication, other medication, or no medication in utero? Participants will\n\n   * complete a psychiatric interview and questionnaires while pregnant;\n   * donate blood from the mother and from the umbilical cord at delivery\n   * have their babies participate in infant behavior evaluations and an EEG procedure.\n\nResearchers will compare these outcomes among individuals who were treated either with antipsychotic medication, with psychotropic medications of other classes, and with no medication, to see if psychiatric benefits for the mother and health outcomes for mother and child differ among these three types of treatment.",[289,290],"Antipsychotics","Pregnancy",[292,293,294,295,296],"antipsychotic","pregnancy","severe mental illness","neonatal adaptation syndrome","neurodevelopment",{"date":180,"type":38},{"date":299,"type":38},"2023-09-29",{"date":301,"type":22},"2028-01-01",{"name":44,"class":45},{"id":304,"slug":4,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":284,"minAge":54,"maxAge":4,"enrollmentInfo":310,"targetDuration":311,"studyType":111,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":276},"100469562","NCT05394428","A Multi Center Study of Sexual Toxicities After Radiotherapy","Novel Functional Anatomic and Biomarker Indices of Radiation-Induced Female Sexual Toxicities in a Multi-Center Cohort","STAR","Inclusion Criteria:\n\n* Patients with female sexual organs ages 18 and older.\n* Patients must meet at least one of the following two criteria:\n\n  * have been sexually active in the 36 months prior to initiating cancer treatment.\n  * have the intent to be sexually active in the 24 months following treatment..\n* Patients must be able to provide consent and be willing to participate.\n* Patients must have primary anal, rectal, cervical, uterine, vaginal, or vulvar cancer planned to receive pelvic radiotherapy.\\*\\* Patients must have an Eastern Cooperative Oncology Group performance status \\\u003C=2.\n\nExclusion Criteria:\n\n* planned for or undergone extensive pelvic surgery (e.g. pelvic exenteration, non-TME techniques, or surgeries otherwise affecting pudendal neurovasculature);\n* have clinically or radiologically detectable widespread metastasis;\n* have limited life expectancy due to comorbid disease;\n* have a personal history of cancer other than non-melanoma skin cancer in the last 5 years;\n* have contraindications or strong relative contraindications to radiotherapy at baseline as determined by the treating radiation oncologist (pregnancy, lactation, genetic susceptibility to cancer from ionizing radiotherapy, connective tissue disorders, inflammatory\u002Firritable bowel disease, history of prior pelvic radiotherapy).\n* have persistent, infectious gastroenteritis, colitis or gastritis;\n* have persistent or chronic diarrhea of unknown etiology; have recurrent or untreated GI infection (clostridium difficile or H. pylori);\n* have current or recurrent vaginal infection;\n* have current or recent antibiotic use (within 2 months).\n\nPatients may be enrolled regardless of previous local or systemic treatments received prior to enrollment in the STAR Study.\n\nPatients may be enrolled on the STAR Study concurrently with another study or clinical trial.",{"count":57,"type":22},"2 Years","The purpose of this research is to understand how radiotherapy and other cancer treatments impact sexual function in female cancer patients and to try to answer a question about why some patients who receive radiotherapy are more likely to have side effects than others. The results of this study may improve our understanding of why sexual side effects occur and in turn develop predictive models and biomarkers of sexual side effects and other side effects that may impact sexual function. The results of this study may also lead to improvements in the techniques used to deliver radiotherapy or the development of interventions that will prevent or reduce sexual side effects and improve quality of life for female patients with cancer.",[314],"Malignant Neoplasms",{"date":180,"type":38},{"date":317,"type":38},"2022-10-04",{"date":319,"type":22},"2027-08-31",{"name":44,"class":45},{"id":322,"slug":4,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":46},"100634627","NCT07542145","MDMA Assisted Therapy for BN","MDMA Assisted Therapy for Bulimia Nervosa: A Treatment Development Protocol","Inclusion Criteria:\n\nParticipants will be included in the protocol if they meet the following criteria:\n\n* At least 18 years of age\n* Meet criteria for Bulimia Nervosa as measured by the EDA-5\n* Able to provide written, informed consent\n* Able to swallow pills\n* Agree to have study visits recorded, including Experimental Sessions and non-medication therapy sessions\n* Provides a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable\n* Agrees to inform the investigators within 48 hours of any medical conditions and procedures\n* If able to become pregnant, must have a negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate contraceptive methods through 10 days after the last Experimental Session. Adequate contraceptive methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e., condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom). 'Not able to become pregnant' is defined as permanent sterilization, postmenopausal, or assigned male at birth\n* Agrees to the lifestyle modifications\n* Live within reasonable driving distance of the study site (equal to or less than an estimated 2-hour drive from the study site).\n* Have an identified Primary Care Physician (PCP) and provide consent for the investigator to communicate with PCP, as needed.\n* Current or past treatment were not successful to retain remission (i.e., continued to meet criteria for BN) despite participating in at least one ED-specific episode of treatment (inpatient, residential, partial hospitalization, intensive outpatient), as confirmed by medical records, by a general practitioner, or by a specialist in ED.\n* Are medically stable according to screening 12-lead Electrocardiogram (ECG), blood pressure monitoring, blood and urine laboratory screening results, and medical history.\n\nExclusion Criteria:\n\nParticipants will be excluded from participation for the following reasons:\n\n* Alanine transaminase (ALT) \\[or aspartate transaminase (AST)\\] \\> 2 x upper limit of normal (ULN). Total bilirubin \\> 1.5 x ULN (isolated bilirubin \\> 1.5 x ULN is acceptable if total bilirubin is fractionated and direct bilirubin \\\u003C 35%).\n* Estimated glomerular filtration rate (eGFR) less than 60.\n* Current unstable liver or biliary disease per investigator assessment defined by presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert's syndrome, asymptomatic gallstones, and chronic stable hepatitis B (e.g., the presence of hepatitis B surface antigen or positive hepatitis C antibody test result without evidence of active infection at screening or within 3 months prior to starting study intervention) is acceptable if the participant otherwise meets entry criteria.\n* Self-induced vomiting of over 14 times per week\n* Symptomatic Hepatitis C virus (HCV)\n* Moderate alcohol or cannabis use disorder (meets \\> 3 of 11 diagnostic criteria per DSM-5) or moderate alcohol or cannabis use disorder in early remission for the 3 months prior to enrollment (meets 4 or 5 of 11 diagnostic criteria per DSM-5)\n* Diabetes Type 1 or Unstable Type 2 Diabetes\n* Untreated hypothyroidism\n* Are likely, in the investigator's opinion and via observation during the Preparatory Period, to lack social support or a stable living situation\n* Have used Ecstasy (material represented as containing MDMA) more than 10 times within the last 10 years or at least once within 6 months of the first Experimental Session;\n* Have previously participated in a MAPS-sponsored MDMA clinical trial\n* Have any current problem which, in the opinion of the investigator or study clinician, might interfere with participation\n* Have hypersensitivity to any ingredient of the IMP (Investigational Medicinal Product)\n* Have received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment\n* Have a history of or a current primary psychotic disorder, bipolar disorder 1 assessed via CAT-MH and confirmed via clinical interview or dissociative identity disorder assessed via DDIS and confirmed via clinical interview\n* Have current major depressive disorder with psychotic features assessed via CAT-MH\n* Have a current moderate (not in early remission in the 3 months prior to enrollment; meets 4 or 5 of 11 diagnostic criteria per DSM-5) or severe alcohol or cannabis use disorder within the 12 months prior to enrollment (meets at least 6 of 11 diagnostic criteria per DSM-5)\n* Have an active illicit drug or prescription drug substance use disorder at any severity (other than cannabis) within 12 months prior to enrollment\n* Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion. Any participant who is likely to require hospitalization related to suicidal ideation and behavior, in the judgment of the investigator, will not be enrolled. Any participant presenting with the following on the Baseline C-SSRS will be excluded: a. Suicidal ideation score of 4 or greater within the last month of the assessment at a frequency of once a week or more; b. Suicidal ideation score of 5 within the last 6 months of the assessment; c. Any suicidal behavior, including suicide attempts or preparatory acts, within the last 6 months of the assessment. Participants with non-suicidal self-injurious behavior may be included if approved by the study clinician\n* Would present a serious risk to others as established through clinical interview and contact with treating psychiatrist\n* Require ongoing concomitant therapy with a psychiatric medication with exceptions described the Concomitant Medications Section\n* Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, or aneurysm. Participants with other mild, stable chronic medical problems may be enrolled if the study physician and Sponsor-investigator agree the condition would not significantly increase the risk of MDMA administration or be likely to produce significant symptoms during the study that could interfere with study participation or be confused with side effects of the IMP. Examples of stable medical conditions that could be allowed include, but are not limited to Diabetes Mellitus (Type 2), Human Immunodeficiency Virus (HIV) infection, Gastroesophageal Reflux Disease (GERD), etc. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism would require exclusión\n* ASCVD Risk Estimator 10-year cardiovascular risk of 7.5% or higher\n* Duke Activity Status Index (DASI) METs score less than 4\n* Have a diagnosis of uncontrolled essential hypertension which is assessed using the recommended criteria of the American Heart Association for Stage 2 hypertension (values of 140\u002F90 milligrams of Mercury \\[mmHg\\] or higher assessed on three separate occasions)\n* Have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease\n* Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation\n* Have a history of supraventricular arrhythmia within the last 12 months. Participants with a history of an allowable supraventricular arrhythmia (see list below) more than 12 months prior to screening and in the absence of any accessory pathway may be enrolled if successfully treated at least 12 months prior and cleared by a cardiologist, and the study clinician. These arrhythmias may include, and must be limited to, paroxysmal supraventricular tachycardia, paroxysmal atrial tachycardia, or atrial fibrillation that has been successfully treated (e.g., with ablation or cardioversion) at least 12 months previously. Atrial flutter or other arrhythmias will be excluded\n* Have a marked baseline prolongation of QT\u002FQTc interval (e.g., repeated demonstration of a QTcF interval \\>450 milliseconds \\[ms\\]\n* Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)\n* Require use of concomitant medications that prolong the QT\u002FQTc interval during Experimental Sessions. Refer to Concomitant Medications Section\n* Have history of hyponatremia or hyperthermia\n* Weigh less than 48 kilograms (kg)\n* Are pregnant or nursing or are able to become pregnant and are not practicing an effective means of contraception\n* Have a blood or needle phobia that interferes with obtaining necessary blood work.\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the sponsor-investigator or study clinician, contraindicates participation in the study.\n* Expressed that they are not comfortable in participating in therapy and conducting assessments in English.\n* Blood disorder or infection indicated by CBC assay that would be contraindicated for MDMA.\n* Thyroid condition (hyperthyroidism) indicated by TSH that would prevent body temperature regulation and be contraindicated for MDMA\n* Urinalysis results indicating electrolytes\u002Fkidney disfunction",{"count":136,"type":22},[329],"PHASE1","This project will evaluate MDMA Assisted Therapy (MDMA-AT) assisted psychotherapy for the treatment of Bulimia Nervosa (BN) over a 10-week period. Preliminary data suggests that MDMA can facilitate heightened openness and reduce anxiety. This study will determine whether MDMA-assisted therapy can serve as a new treatment for BN. Participants are assigned to one of three groups: MDMA-AT, MDMA-AT-BN, and Standard Treatment (ST). MDMA groups include three experimental session that include dosing, which are each followed by three integrative sessions and also include 12 psychotherapy sessions. A follow-up will take place at 6-months post baseline.",[332],"Bulimia Nervosa",[332,334,335,336,337],"MDMA-assisted therapy","Eating Disorders","Binge Eating","BN","2026-06-17",{"date":180,"type":38},{"date":341,"type":38},"2026-05-22",{"date":343,"type":22},"2028-04-30",{"name":44,"class":45},{"id":346,"slug":4,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":17,"minAge":351,"maxAge":54,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":46},"100497945","NCT05763849","Interoceptive Exposure for Adolescents With Low Weight Eating Disorders","A Confirmatory Efficacy Study of Interoceptive Exposure for Adolescents With Low Weight Eating Disorders","Inclusion Criteria:\n\n* Aged 12-18\n* Speak English\n* Permission from pediatrician or equivalent to receive outpatient care\n* Clinically significant restriction of food intake by EDA-5 or evidence of persistent food avoidance from patient or guardians\n* Evidence of the inability to maintain greater than minimally low body weight based on BMI for age percentiles and growth trajectories\n\nExclusion Criteria:\n\n* Comorbid psychotic or bipolar disorder\n* Active suicidal ideation\n* Current substance dependence\n* Psychiatric medication initiated or dosage changes \\\u003C2 weeks from baseline\n* Major medical illness (e.g., diabetes mellitus, Crohn's disease, etc.)","12 Years",{"count":353,"type":22},120,[25],"This project includes a parallel group randomized controlled trial comparing two psychological treatments: 1) Exposure-based Family Therapy (IE) vs. 2) Family Based Therapy (FBT) for low weight eating disorders with 12 month follow-up. Primary outcomes are expected body weight and clinical impairment. Three mechanisms of change (Autonomous Eating, Non-Judgmental Body Awareness, and Extinction Learning) will be examined in a process mediation models of change.",[357],"Anorexia Nervosa",{"date":180,"type":38},{"date":360,"type":38},"2023-03-14",{"date":362,"type":22},"2028-01",{"name":44,"class":45},{"id":365,"slug":4,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":17,"minAge":370,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":379,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":46},"100587617","NCT06930716","Paired Vagus Nerve Stimulation in Mobilization of Patients With Prolonged Disorders of Consciousness","Use of Paired Vagus Nerve Stimulation in Mobilization of Patients With Prolonged Disorders of Consciousness: A Pilot Feasibility Study","Inclusion Criteria:\n\n* Patients with a diagnosis of pDOC (includes coma, VS\u002FUWS, MCS, MCS +, MCS-) as defined as disorder of consciousness (DOC) greater than 6 weeks post onset\n* Patients deemed medically safe to participate in physical therapy (PT) as evaluated by the study physicians.\n\nExclusion Criteria:\n\n* Patients who have emerged from MCS (CRS-R score 6 on Motor Function scale and\u002For 2 on Communication Scale).\n* Patients medically unsafe for participation in PT as indicated by one of the study physicians (including but not limited to those receiving intravenous sedation, those with integumentary breakdown or known pressure injuries, those with cardiovascular or cerebrovascular conditions precluding initiation of physical therapy \\[ie uncontrolled intracranial pressure, severe symptomatic orthostatic hypotension, etc.).\n* Patients with DOC less than 6 weeks post onset will also be excluded.\n* Patients who do not meet technical requirements of the RTTM device will be excluded\n\n  * weighing greater than 135 kg\n  * length of legs below 75 cm or above 100 cm,\n  * fixed contractures of lower extremity including hip, knee, ankle, or foot).\n* Does not have an identified care partner or legally authorized representative to consent to participation","22 Years",{"count":372,"type":22},15,[25],"Prolonged disorders of consciousness (pDOC) are defined as DOC lasting \\>1 year post injury for patients with Traumatic Brain Injury (TBI) and \\>3 months post injury for patients with non-TBI and at present there are limited treatments that reliably lead to enhanced prognosis. The rehabilitation process throughout the continuum of care for patients with pDOC necessitates restorative strategies to facilitate arousal and functional recovery and coordinated medical management. Rehabilitation interventions for patients with DOC and pDOC have evolved in the past decade, with an emerging body of evidence highlighting the benefits of rehabilitation intervention even in the acute. While there is data to support the individual utility of these modalities, no work to date has investigated the benefits of pairing transauricular vagus nerve stimulation (taVNS) and robotic tilt table mobilization (RTTM) to maximize functional recovery in patients with pDOC. This study will report on the safety, feasibility, and preliminary short- and long-term outcomes of RTTM with simultaneously paired Transcutaneous auricular vagus nerve stimulation (taVNS) for Severe Acquired Brain Injury (SABI) patients with pDOC . Fifteen (15) participants will be recruited and complete a 12-week rehabilitation protocol using paired taVNS and RTTM. Once participants have been screened and enrolled in the study, they will complete three study phases: T1: a baseline observation of standard of care T2, intervention, and T3 longitudinal follow up.",[376,377,378],"Consciousness Disorders","Brain Injury","Altered Level of Consciousness",[380,381,382],"Therapy","Rehabilitation","Neuromodulation","2026-06-16",{"date":269,"type":38},{"date":386,"type":38},"2025-08-12",{"date":388,"type":22},"2027-12-30",{"name":44,"class":45},{"id":391,"slug":4,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":396,"targetDuration":398,"studyType":111,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":46},"100452547","NCT05172921","Environmental Factors and Thyroid Cancer","The Role of Environmental Factors in Thyroid Cancer","Inclusion criteria:\n\n* Bethesda category III, IV, V or VI following Fine Needle Aspiration; if a patient has a benign tumor following surgery, patient data\u002F samples will be stored to serve as benign control in potential future projects.\n* Age 18 years and older\n* Surgical candidate\n* Ability to provide informed consent\n\nExclusion criteria:\n\n* History of thyroid cancer\n* Completion surgery candidate\n* Pregnant women or other vulnerable patients (e.g. wards of the state, prisoners)",{"count":397,"type":22},500,"4 Years","Thyroid cancer incidence has been steadily increasing and has nearly tripled since the 1970's in the US and worldwide. Early detection of small, papillary thyroid cancers using high quality diagnostic imaging explains only about 50% of this increased incidence, suggesting that there is a true increase in the occurrence of thyroid cancer and that changes in the prevalence of environmental risk factors might play a role in thyroid cancer etiology and progression. Yet, the cascade of environmental triggers linked to thyroid cancer remains elusive.\n\n'Exposomics' studies all health relevant chemical exposures that an individual experiences, and leverages metabolomic platforms to estimate the \"internal\" environment, informing both exogenous exposures and the metabolic products that lead to, or arise from, disease. Besides exposure to ionizing radiation as known modifiable risk factor, epidemiological evidence suggests that exposure to endocrine disrupting chemicals may be a potential thyroid cancer risk factor due to their known effects on thyroid function. However, these studies relied either on exposure questionnaires which are susceptible to recall bias, or used a limited set of targeted biomarkers measured after diagnosis for testing associations with case-control status, and not thyroid cancer prognosis. Further, the molecular basis for observed associations with thyroid cancer remains unclear.\n\nTo address the overall hypothesis that environmental exposures alter metabolic pathways and therefore affect thyroid cancer prognosis, small amounts of blood will be collected using dried blood microsampler technology (e.g. Mitra® sampling devices), which is minimally invasive and can be used to collect repeated blood measurements at home, without the need for specialized training. These dried blood samples will be used to perform metabolomics experiments, which describe the sum of exogenous exposures, metabolic alterations, and biological response. Additional exposure assessment will be performed using an exposure questionnaire. These results will be associated with thyroid cancer prognosis, e.g. disease-specific survival, disease recurrence, and mutational profiles, thus investigating the role of environmental exposures in the development of more aggressive forms of thyroid cancer.",[401],"Thyroid Cancer","2026-06-15",{"date":338,"type":38},{"date":405,"type":38},"2022-02-03",{"date":407,"type":22},"2035-06",{"name":44,"class":45},{"id":410,"slug":4,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":415,"minAge":54,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":419,"conditions":420,"keywords":423,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":46},"100595028","NCT07027124","Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","Neoadjuvant ADT and Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in NCCN High-risk and Molecularly Stratified Prostate Cancer Patients","Inclusion Criteria:\n\n* Male Age ≥ 18 years at the time of consent\n* Subjects must have histopathologically confirmed adenocarcinoma of the prostate\n* Subjects must have unfavorable intermediate and high-risk localized or locally advanced prostate cancer (Gleason score ≥7 (4+3) and absence of distant metastasis or non-regional nodal involvement.\n* Subjects must be risk-stratified at biopsy and their cancer should have all the molecular features given below at baseline.\n\n  1. Decipher Genomic Classifier \\>0.45 (interpreted from decipher report) and\u002F or\n  2. Luminal B subtype (interpreted from decipher report).\n* The patient must have a performance status of 0-1 as determined by criteria set forward by the eastern cooperative oncology group.\n* Subjects with prior neoadjuvant hormonal therapy are allowed if they meet the following criteria.\n\n  * have completed all treatments ≥ 12, months ago.\n  * Recovered from all AEs due to previous therapies.\n* If subject has had a major surgery, he should have recovered from all complications and toxicities prior to enrolling in the study.\n* Adequate organ and marrow function as defined below:\n\n  * Hematological\n  * Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL\n  * Platelets ≥ 100,000\u002Fmcl\n  * Hemoglobin (Hb) ≥ 9 g\u002FdL Hepatic\n  * total bilirubin ≤ 1.5 mg\u002Fdl (except in patients with gilbert syndrome who can have total bilirubin \\\u003C3.0 mg\u002Fdl)\n  * Aspartate aminotransferase (AST) ≤ 2.5 x ULN\n  * Alanine aminotransferase (ALT) ≤ 2.5 x ULN Renal\n  * Creatinine OR Creatinine ≤ 1.5 ULN OR\n  * Calculated creatinine clearance Creatinine clearance ≥ 30 ml\u002Fmin\n  * Men must agree to use a condom and not father a child or donate sperm for the duration of the study and for 90 days after completion of therapy. Subject must agree to partner use of an additional contraceptive method when having intercourse with women of childbearing potential (WOCBP).\n  * Ability to understand and the willingness to sign a written informed consent.\n  * Subjects who are HBs Ag positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.\n\nNote: Subjects should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.\n\n* Hepatitis B screening tests are not required unless:\n\n  * Known history of HBV infection\n  * As mandated by local health authority\n* Subjects with a history of HCV infection are eligible if HCV viral load is undetectable at screening.\n\nNote: Subjects must have completed curative anti-viral therapy at least 4 weeks prior to randomization.\n\n* Hepatitis C screening tests are not required unless:\n\n  * Known history of HCV infection\n  * As mandated by local health authority\n* Subjects with a known history of Human immunodeficiency virus (HIV) infection are eligible as long as they have an undetectable viral. HIV positive participants must be taking stable ART for ≥ 12 weeks and have an undetectable HIV viral load within 28 days before enrollment. Minor fluctuations up to 200 copies\u002FmL are acceptable.\n\nExclusion Criteria:\n\n* Subjects with metastatic disease\n* Subjects with Gleason score ≤7 (3+4)\n* Subjects with Biopsy Decipher score ≤0.45.\n* Subjects have had prior hormonal therapy (please see inclusion criteria for exceptions).\n* Subjects have had prior radiation therapy or chemotherapy for prostate cancer.\n* Subjects with active cardiac disease defined as having any of the following within 6 months prior to the start of treatment:\n\n  * myocardial infarction,\n  * severe\u002Funstable angina pectoris,\n  * congestive heart failure,\n  * hospitalization for any cardiac event\n* Subject has active GI disorder that will interfere with absorption of study drug Darolutamide Subject has prior treatment with androgen receptor inhibitors, such as apalutamide, Darolutamide, enzalutamide, abiraterone acetate or other investigational CYP17 inhibitor.\n* Inability to swallow oral medications.\n* Subject has active infection requiring systemic therapy within 7 days of Week 1.\n* Subject has received prior therapy with anti-PD1, anti-PDL1, anti-PDL2 or with other checkpoint inhibitors or T-cell costimulatory\u002Finhibitory agents (e.g., CD137, OX-40, CTLA4).\n* Subject with an active viral Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive or detectable \\[qualitative\\] Hepatitis b virus \\[HBV\\] DNA or defined as Hepatitis V virus \\[HCV\\] ribonucleic acid \\[RNA\\] \\[qualitative\\] is detected), known Human Immunodeficiency virus (HIV) infection with detectable viral load, or chronic liver disease with a need of treatment.\n* Subject has a known active or known history of TB (Bacillus tuberculosis) or active history of non-infectious pneumonitis.\n* Subject who are immunodeficient or are receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days of study intervention. Topical or inhaled steroids are permitted in absence of immunodeficiency or autoimmune disease.\n* Subject have active auto-immune disease that has required systemic therapy (use of disease modifying agents, corticosteroids, or immunosuppressive drugs) in the past 2 years. However, subjects receiving replacement therapy (e.g., insulin, thyroxine, or physiological corticosteroid replacement therapy for adrenal and pituitary insufficiency) are eligible.\n* Has history or current evidence of any condition, therapy that might confound results of the study. - Has known psychiatric, epileptic or substance abuse history or disorder that would interfere with participant's ability to cooperate with the requirements of the study.\n* Subjects with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\n* Known history of allergic reactions attributed to compounds of similar chemical or biologic composition to Agent(s) or other agents used in study.","MALE",{"count":136,"type":22},[418],"PHASE2","This is a single-arm, phase II study of neoadjuvant combination therapy of Androgen Deprivation Therapy (ADT), \\[Gonadotropin-Releasing Hormone (GnRH) agonist Leuprolide\\], androgen receptor (AR)-antagonist Darolutamide and Pembrolizumab in a stratified high-risk localized prostate cancer cohort, followed by adjuvant treatment with Pembrolizumab (12 cycles) post-radical prostatectomy (RP).\n\nPatients with National Comprehensive Cancer Network (NCCN) high-risk non-metastatic prostate cancer (localized or locally advanced) (defined as Gleason ≥8, disease stage \\>=cT3a, or PSA l \\>20 ng\u002FmL) will be risk-stratified at a biopsy using Decipher, a commercial standard-of-care diagnostic assay. Patients satisfying all three criteria of high-risk genomic characteristics listed below as per the Decipher grid results will be enrolled in the study:\n\n1. Decipher Genomic classifier, GC\\>0.6\n2. AR activity score\u002FAR-output gene signature (ARoS)\\>11.0\n3. High Luminal B score\u002F PAM50 subtype signature",[421,422],"Prostate Cancer","High-risk Prostate Cancer",[421,424,425,426,427],"Immunotherapy","Pembrolizumab","Darolutamide","ADT","2026-06-12",{"date":383,"type":38},{"date":431,"type":22},"2026-05-21",{"date":433,"type":22},"2031-05-02",{"name":44,"class":45},{"id":436,"slug":4,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":46},"100514778","NCT05982925","Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders","Longitudinal Investigation of Cortical Demyelination and Meningeal Inflammation in Multiple Sclerosis and Related Disorders","Inclusion Criteria:\n\n* 18 years old\n* able to provide consent in English\n* able to undergo MRI\n\nExclusion Criteria:\n\n* contraindication to MRI\n* pregnancy",{"count":442,"type":22},170,"In this protocol, a combination of MRI, blood, and cerebrospinal fluid (CSF) analysis will be used to understand the natural history, underlying immunologic mechanisms, and clinical implications of central nervous system (CNS) lesions, in particular lesions in the cerebral cortex, in multiple sclerosis (MS) and other inflammatory and autoimmune disorders affecting the CNS. Patients with these disorders, as well as healthy controls, will undergo baseline clinical evaluation and testing, bloodwork, and MRI, with follow up clinical evaluation, bloodwork, and MRI at years 1, 3, and 6. Additional MRIs may be performed in patients with possible new lesion formation or to compare MRI techniques. Lumbar puncture will be performed on participants who are not currently being treated with disease modifying therapies and who are willing to undergo the procedure.",[445,446,447],"Multiple Sclerosis","Neuromyelitis Optica","Demyelinating Autoimmune Diseases, CNS",{"date":402,"type":38},{"date":450,"type":38},"2022-05-06",{"date":452,"type":22},"2034-07-31",{"name":44,"class":45},{"id":455,"slug":4,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":284,"minAge":54,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":463,"conditions":464,"keywords":467,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":475,"locationsCount":46},"100642361","NCT07651956","Remimazolam Versus Dexmedetomidine for Sedation During Neuraxial","Remimazolam Versus Dexmedetomidine for Procedural Sedation During Neuraxial Anesthesia Placement For Scheduled Cesarean Delivery","Inclusion Criteria:\n\n* Pregnant patient scheduled for cesarean delivery\n* ≥ 18 years old\n* ≥ 37 weeks gestational age\n\nExclusion Criteria:\n\n* Pregnant patients \\\u003C 18 years old\n* Pregnant patients \\\u003C 37 weeks gestational age\n* Has known hypersensitivity to benzodiazepines or dexmedetomidine\n* Has history of chronic benzodiazepine use or misuse",{"count":176,"type":22},[462],"PHASE4","Patients presenting for a scheduled cesarean delivery who require a neuraxial anesthetic will be randomized to receive intravenous remimazolam or dexmedetomidine for procedural sedation during the placement of their spinal or epidural anesthesia.",[465,466],"Pregnant People","Anxiety",[468,469,470],"Anxiolysis","Remimazolam","Dexmedetomidine","2026-06-11",{"date":383,"type":38},{"date":272,"type":22},{"date":185,"type":22},{"name":44,"class":45},{"id":477,"slug":4,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":492,"locationsCount":46},"100484574","NCT05589818","Pembrolizumab for Advanced NSCLC and PS 2-3","A Phase II Study of the Effects of Pembrolizumab on Quality of Life for Patients With Treatment-Naïve, Advanced or Metastatic NSCLC and Poor Performance Status","Inclusion Criteria:\n\n* Men and women, aged 18 years and older, with locally advanced NSCLC who are ineligible for definitive surgical resection or concurrent chemoradiation, or metastatic NSCLC\n* Patients must not have received any systemic therapy for metastatic cancer\n* Patients must not have received any PD-1 or PD-L1 inhibitor\n* ECOG performance status of 2 or 3 at the time of consent and on the first day of therapy\n* Patients may not have a molecular alteration in ALK, ROS1, EGFR, BRAF, NTRK, RET, MET, or any other gene for which first-line FDA approved targeted therapy exists.\n* Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS directed therapy is not required and is unlikely to be required during the first cycle of therapy.\n* Patients with HIV on effective anti-retroviral therapy with an undetectable viral load within 6 months are eligible for this trial.\n* Adequate organ and marrow function as defined below:\n\n  * Leukocytes ≥ 3,000\u002FmcL\n  * Absolute neutrophil count ≥ 1,000\u002FmcL\n  * Platelets ≥ 100,000\u002Fmcl\n  * Total bilirubin ≤ 1.5 x ULN\n  * AST (SGOT)\u002FALT (SPGT) ≤ 3 x ULN or ≤5 x ULN if liver metastases present\n  * GFR (Cockroft-Gault) ≥ 30 mL\u002Fmin\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 3 days prior to C1D1 of pembrolizumab therapy. For the purposes of this trial, WOCBP are defined as women who have had a menstrual period within the last 48 months.\n* Provision of signed and dated informed consent form\n* Ability to take the study medication, and complete the study questionnaires\n* Stated willingness to comply with all study procedures for the duration of the study\n* For women of reproductive potential, agreement to use highly effective contraception during study treatment and for at least 4 months after the final dose\n* For men of reproductive potential, agreement to use condoms or other methods to ensure effective contraception with female partners of reproductive potential\n\nExclusion Criteria:\n\n* Autoimmune conditions requiring \\>10mg prednisone (or its equivalent) of daily therapy or other systemic immunosuppressive therapy.\n* Patients who are receiving other investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Patients with known leptomeningeal disease for which CNS therapy is required\n* Pregnant or lactating patients",{"count":483,"type":22},45,[418],"This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radiation. Patients will be eligible for the trial if ISMMS reviewed samples from tumor biopsy have a PDL-1 TPS ≥ 1% and have ECOG performance status rated 2 or 3. All patients will receive anti PD-1 therapy with pembrolizumab 200mg IV every 3 weeks, during which patients will also undergo serial QOL assessments.\n\nThis trial will follow a phase II single arm, open label design. The study will enroll 45 patients evaluable for the primary endpoint of which will be change in QOL as measured by the EORTC's QLQ-C30 between Day 1 and Day 84 +\u002F- 7 days. Secondary outcomes including evaluation for development of confounding mental health conditions will be evaluated via serial HADS assessments. Concomitant radiographic assessment with PET\u002FCT, regardless of the doses of pembrolizumab received, will allow for evaluation of secondary efficacy outcomes, including disease response by RECIST 1.1 criteria.",[487],"Non-Small Cell Lung Cancer (NSCLC)",{"date":402,"type":38},{"date":490,"type":38},"2023-12-05",{"date":126,"type":22},{"name":44,"class":45},{"id":494,"slug":4,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":11,"sex":17,"minAge":153,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":508,"locationsCount":74},"100495940","NCT05737732","The Ambient Light Multiple Myeloma Study","Systematic Light Exposure Effects on Circadian Rhythms Entrainment, Inflammation, Neutropenic Fever and Symptom Burden Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation","Inclusion Criteria:\n\n* Multiple Myeloma diagnosis\n* Scheduled to undergo their first Autologous Stem Cell Transplant procedure.\n* 21years or older\n* Able to provide informed consent.\n* English-language proficient\n\nExclusion Criteria:\n\n* Previous Autologous Stem Cell Transplant procedure\n* Pregnancy\n* Eye diseases which limit the ability of light to be processed\n* Secondary cancer diagnosis within the last 5 years\n* Severe sleep disorders\n* History of bipolar disorder or manic episodes\n* Severe psychological impairment\n* Previous use of light therapy\n* Active infection including COVID-19 infection",{"count":110,"type":22},[25],"The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. While receiving these light treatments, participants' sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels and symptoms will be assessed over a 2-month period.",[261],"2026-06-10",{"date":428,"type":38},{"date":506,"type":38},"2023-02-13",{"date":146,"type":22},{"name":44,"class":45},{"id":510,"slug":4,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":46},"100632038","NCT07508488","Deucravacitinib in the Treatment of Cicatricial Alopecias","Inclusion Criteria:\n\n* Participants of any gender, age 18 years or older, at the time of informed consent at Screening\n* Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements.\n* Participant self-reports a history of at least 6 months of moderate-to-severe CA (FFA or CCCA). Diagnosis will be made clinically, and severity assessed with according to the FFASI32 ≥30 and\u002For CHLG ≥3.\n* Participant has a negative Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at screening or within the last 12 months.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP (all female participants, regardless of whether or not they have experienced\u002Freported menarche, are considered WOCBP unless they are permanently sterile or confirmed infertile). A WOCBP who is sexually active must use a contraceptive method that is highly effective, with a failure rate of \\\u003C1%, during the intervention period and for at least 28 days after the last dose of study intervention. And if a WOCBP, must have a negative highly sensitive serum pregnancy test at the screening visit and a negative urine pregnancy test at baseline performed before the first dose of study intervention.\n* Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nExclusion Criteria:\n\n* Participant's cause of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia.\n* Participant has a history of CA for \\> 5 years since the disease onset, severe fibrosing disease, or very rapid hair loss at screening.\n* Participant has a history of moderate to severe keloids on the scalp, as determined by clinical examination at screening. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.\n* Other scalp disease that may impact assessment (e.g., scalp psoriasis, dermatitis, etc.).\n* Participant is pregnant or breastfeeding.\n* Participation in other studies involving investigational drug(s) within 4 weeks or within 5 half-lives (if known), whichever is longer, prior to study entry and\u002For during study participation (de novo patients only).\n* Active systemic diseases that may cause hair loss (e.g., systemic lupus erythematosus, thyroiditis, systemic sclerosis, etc.).\n* Any Psychiatric condition in the opinion of the investigator precludes participation in the study.\n* Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (particularly thyroid disease which can be associated with hair loss), pulmonary, cardiovascular, psychiatric, immunologic\u002Frheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator, the participant is inappropriate for entry into this study, or unwilling\u002Funable to comply with STUDY PROCEDURES.\n* History of thromboembolic events including DVT and PE or history of inherited coagulopathies.\n* Any present malignancies or history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.\n* History of any lymphoproliferative disorder such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.\n* History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.\n* History of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 0.\n* Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 0 or superficial skin infection within 1 week prior to Day 0. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.\n* Considered in imminent need for surgery or with elective surgery scheduled to occur during the study.\n* Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology at the time of screening.\n* Participant has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints, as determined by the PI.\n* Have an active history of alcohol or substance abuse within 1 year prior to Day 0.\n* Participant has received a live attenuated vaccine ≤ 6 weeks prior to study screening.\n* History of adverse systemic or allergic reactions to components of study drug.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, within 8 weeks prior to baseline visit.\n* Use of other non-biologic systemic agent for CA, including, 5α-reductase inhibitors, hydroxychloroquine, or retinoids, within 4 weeks prior to baseline visit.\n* Use of an intralesional corticosteroids or oral JAK inhibitor (tofacitinib, ruxolitinib, or any JAK1\u002FTYK2 product) within 4 weeks prior to the baseline visit.\n* Any previous use of a TYK2 inhibitor.\n* Participant has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus or cyclosporine within 1 week before the baseline visit.\n* Participant has been previously treated with biological drugs in the last 12 weeks for other indications.\n* Participants previously tested with a positive or indeterminable PPD or QFT result, including participants that completed standard tuberculosis therapy.",{"count":515,"type":22},20,[418],"This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline\u002FDay 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.",[519,520],"Central Centrifugal Cicatricial Alopecia","Frontal Fibrosing Alopecia","2026-06-09",{"date":503,"type":38},{"date":524,"type":38},"2026-05-28",{"date":526,"type":22},"2028-09-30",{"name":44,"class":45},{"id":529,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":530,"targetDuration":4,"studyType":23,"phases":531,"briefSummary":26,"conditions":532,"keywords":533,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":539,"locationsCount":46},"100642721",{"count":21,"type":22},[25],[28],[30,31,32,33],"2026-06-05",{"date":503,"type":38},{"date":537,"type":22},"2026-07-01",{"date":42,"type":22},{"name":44,"class":45},{"id":541,"slug":4,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":554,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":46},"100625495","NCT07423377","Vestibular Innovation in Pain 2","Vestibular Innovation in Pain: A Randomized Controlled Trial","VIPR","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Age equal to or \\>18 years old\n* Stated interest in and willingness to receive VCS and to complete the online patient reported outcomes before and after the procedure.\n* Owns or has access to a smart phone or computer to complete outcome measures\n* Fluency in English\n* Diagnosis of Fibromyalgia (FM)\n\n  * Diagnosis by American College of Rheumatology 2016 questionnaire\n  * Pain score 4\u002F10 or more and less than 10\u002F10 on the numeric rating scale at the time of inclusion.\n\nExclusion Criteria:\n\n* History of tympanic membrane injury, rupture, or surgery a. Including tympanostomy, or \"ear tubes,\" and\u002For cochlear implant.\n* Right ear infection within the last 3 months, or current right ear pain.\n* Current pregnancy\n* Bipolar Disorder\n* History of seizures (including non-epileptiform seizures)\n* History of syncope within the last 3 months. a. Not including presyncope or in setting of known medical illness (i.e., heatstroke)\n* Inability to lay supine for 15 minutes\n* Receiving disability benefits for fibromyalgia or involved in litigation related to fibromyalgia.\n* Clinically significant medical, psychological, or behavioral conditions that, in the opinion of the investigator, would compromise participation in the study.\n* History of or current Meniere's Disease\n* History of myocardial infarction (MI), stroke or TIA, or coronary artery bypass graft (CABG) in the last 3 months\n* History of hospitalization for severe hypertension\n* History of vestibular schwannoma or meningioma resection.\n* Patients taking opioid therapy (not including tramadol).",{"count":548,"type":22},56,[25],"Fibromyalgia is the most common centralized pain disorder, affecting up to 3% of the population. Current treatments are incompletely effective, often poorly tolerated, and costly: there remains an urgent need for novel, effective, and well-tolerated therapy. Preliminary data suggests that vestibulocortical stimulation (VCS), or irrigating the external ear canal with temperate water, could rapidly improve pain and quality of life in this cohort. The VIPR trial will assess the efficacy of a single session of VCS - a safe \\& cost-effective bedside technique using a plastic syringe and temperate water - relative to sham in treating pain \\& improving quality of life using validated patient-reported outcomes.",[552,553],"Fibromyalgia","Nociplastic Pain",[555,556],"pain","quality of life",{"date":558,"type":38},"2026-06-08",{"date":560,"type":38},"2026-03-19",{"date":562,"type":22},"2027-07-31",{"name":44,"class":45},""]